Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ.

Pharmacogenomics J. 2012 Aug;12(4):297-305. doi: 10.1038/tpj.2011.5. Epub 2011 Mar 1.

2.

Genetic causes of clopidogrel nonresponsiveness: which ones really count?

Momary KM, Dorsch MP, Bates ER.

Pharmacotherapy. 2010 Mar;30(3):265-74. doi: 10.1592/phco.30.3.265. Review.

PMID:
20180610
3.

Genetic determinants of platelet response to clopidogrel.

Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A.

J Thromb Thrombolysis. 2011 Nov;32(4):459-66. doi: 10.1007/s11239-011-0611-8. Review.

4.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR.

Pharmacogenomics. 2009 Nov;10(11):1799-817. doi: 10.2217/pgs.09.143. Review.

PMID:
19891556
5.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
6.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
7.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
8.

Clopidogrel pharmacogenetics: metabolism and drug interactions.

Close SL.

Drug Metabol Drug Interact. 2011;26(2):45-51. doi: 10.1515/DMDI.2011.002. Review.

PMID:
21819266
9.

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.

Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R.

Heart. 2012 Jan;98(2):100-8. doi: 10.1136/hrt.2011.227652. Epub 2011 Jun 21. Review.

PMID:
21693476
10.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

11.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

12.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
13.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

14.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

15.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
16.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J.

Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x. Review.

17.

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Shahin MH, Johnson JA.

Curr Opin Cardiol. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Review.

18.

Clopidogrel Therapy and CYP2C19 Genotype.

Dean L.

In: Pratt V, McLeod H, Dean L, Malheiro A, Rubinstein W, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2012 Mar 8 [updated 2015 Nov 19].

19.

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.

Brown SA, Pereira N.

J Pers Med. 2018 Jan 30;8(1). pii: E8. doi: 10.3390/jpm8010008. Review.

20.

[Predictive factors for the complication of allogeneic stem cell transplantation].

Onizuka M.

Rinsho Ketsueki. 2011 Aug;52(8):659-66. Review. Japanese. No abstract available.

PMID:
21897072

Supplemental Content

Support Center